Last reviewed · How we verify

NCT03450213

Astigmatism in Keratoconus Patients

Status unknown NA Last updated 17 October 2018
What this trial tests

NA trial testing Pentacam in Keratoconus in 100 participants. Status unknown.

Timeline
1 October 2019
Primary endpoint
1 October 2020
1 October 2021

Quick facts

Lead sponsorAssiut University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposescreening
Enrollment100
Start date1 October 2019
Primary completion1 October 2020
Estimated completion1 October 2021

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

Eligibility, any sex, with Keratoconus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Keratoconus is a bilateral (but usually asymmetrical) non-inflammatory progressive thinning process of the cornea. It manifests as characteristic cone-like ectasia of the cornea associated with irregular stromal thinning, resulting in a cone-like bulge , which causing irregular astigmatism and vision impairment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Pentacam

Trials testing the same drug.

Other recruiting trials for Keratoconus

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03450213.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing